Navigation Links
ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
Date:10/14/2008

- Conference Call to Discuss Results to Be Held at 9:00 A.M. -

EXTON, Pa., Oct. 14 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) third quarter financial results for 2008 are expected to be released on Wednesday, October 29, 2008 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the third quarter financial results for 2008 and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until November 15, 2008. To participate in the conference call, please dial 877-366-0713 (domestic) and 302-607-2000 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in infectious diseases including cytomegalovirus (CMV) and C. difficile. For more information on ViroPharma, visit the company's website at http://www.viropharma.com. ViroPharma routinely posts information that may be important to investors in the Investor Relations and Media sections of our web site, including press releases. We encourage investors to consult these sections of our web site regularly for important information about ViroPharma.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma to Present at Three October Healthcare Conferences
2. ViroPharma to Present at Three September Healthcare Conferences
3. ViroPharma To Acquire Lev Pharmaceuticals
4. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
5. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
6. ViroPharma to Present at Two Upcoming Healthcare Conferences
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
9. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
10. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
11. ViroPharma to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... studies (such as insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or ... Salivary Insulin Assay from Salimetrics’ SalivaLab , the relationship between insulin and ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017 ... company, and Beyond Type 1, a not-for-profit advocacy and ... today announced a grant from Beyond Type 1 to ... type 1 and other insulin-requiring diabetes.  ... innovative stem cell-derived cell replacement therapies with a focus ...
Breaking Biology Technology:
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
Breaking Biology News(10 mins):